Table I.
Characteristics of included articles
| Author | Year | Country | Study Design | Na | Risk Group | Proportion Refusing | Reported Inclusion/Exclusion Criteria | Adherence Measure | Drug Regimen | Reported Side Effects | Loss to Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Minas(44) | 2012 | Australia | Prospective | 160 | Mixed | NR | N | NR | NR | N | NR |
| Bentz(14) | 2010 | France | RCT | 39 | Mixed | NR | Y | Self report | 3-drug | Y | 27.8% at day 15 |
| Rey(30) | 2008 | France | Retrospective | 629 | Mixed | 3.0% | N | Retention in treatment | NR | Y | 26.3% after starter kit; 41.9% at day |
| Lacombe(13) | 2006 | France | Retrospective | 137 | Mixed | NR | Y | NR | 3-drug | Y | NR at day 28 |
| Sonder(25) | 2010 | Netherlands | Prospective | 259 | MSM | NR | N | NR | 3-drug | Y | 5.9% at day 28 |
| Tissot(29) | 2010 | Switzerland | Retrospective | 483 | Mixed | 2.2% | Y | NR | 3-drug | Y | 19.5% at day 28 |
| McCarty(45) | 2011 | UK | Retrospective | 50 | Mixed | NR | N | NR | 2-drug | Y | 30.6% at day 28 |
| Day(46) | 2006 | UK | Retrospective | 45 | MSM | NR | Y | NR | NR | Y | 31.1% at day 28 |
| Diaz-Brito(34) | 2011 | Spain | RCT | 161 | Mixed | NR | Y | Self report | 3-drug | Y | 15.7% at day 28 |
| Landovitz(47) | 2012 | US | Prospective | 35 | MSM | NR | Y | Pill count/Self report | 2-drug | Y | NR at day 28 |
| Mayer(15) | 2012 | US | Prospective | 84 | MSM | NR | Y | Pill count | 3-drug | Y | 15% at day 28 |
| Roland(33) | 2011 | US | RCT | 402 | Mixed | NR | Y | Self report | 3-drug | Y | 10.3% at 28 days |
| Shoptaw(48) | 2008 | US | Prospective | 84 | Mixed | NR | Y | Pill count/Self report | 2-drug | Y | 14.3% at day 28 |
| Mayer(16) | 2008 | US | Prospective | 231 | MSM | NR | Y | Pill count | 2-drug | Y | 37.7% at day 28 |
| Kahn(49) | 2001 | US | Prospective | 346 | MSM | NR | Y | Self report | 2-drug | Y | 9.2% at day 28 |
| Schechter(17) | 2004 | Brazil | Prospective | 97 | MSM | 43% | Y | Pill count/Self report | 2-drug | Y | 2.0% at day 28 |
| Izulla(21) | 2012 | Kenya | Prospective | 326 | FSW | NR | Y | Self report | 2-drug | N | 44.5% at 10 days |
Abbreviations: RCT (randomized controlled trial); MSM (men who have sex with men); FSW (female sex worker); Y (Yes); N (No); NR (not reported)
a
N includes all patients who initiated PEP, excluding those who tested HIV-positive at baseline or whose source tested HIV-negative and those who collected a full 28-day course of PEP but did not return for follow-up at 28 days